Yes, GSTs, particularly GSTP1, can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. Elevated GSTP1 levels in blood, urine, or tissues may indicate the presence of cancer or predict resistance to specific chemotherapy agents. Measuring GST activity or expression can help tailor personalized treatment strategies for patients.
